Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09AX Other drugs for disorders of the musculo-skeletal system
M09AX09 Onasemnogene abeparvovec
D11559 Onasemnogene abeparvovec (USAN/INN) <US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Onasemnogene abeparvovec
D11559 Onasemnogene abeparvovec (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
49 Other agents affecting cellular function
490 Other agents affecting cellular function
4900 Other agents affecting cellular function
D11559 Onasemnogene abeparvovec (USAN/INN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Signaling molecules
Spliceosome
SMN1
D11559 Onasemnogene abeparvovec (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
Cellular and gene therapy products
D11559
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11559
New drug approvals in Japan [br08318.html]
Cellular and gene therapy products
D11559
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11559
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D11559
